Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP) started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNPFree Report) in a research report report published on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 2.9 %

NASDAQ:TTNP opened at $7.21 on Tuesday. Titan Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $16.60. The company has a market cap of $6.59 million, a PE ratio of -0.88 and a beta of 1.33. The company has a 50 day simple moving average of $7.34 and a two-hundred day simple moving average of $7.17.

Titan Pharmaceuticals Company Profile

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.

See Also

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with's FREE daily email newsletter.